Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Pfeffer

Showing results (621-630 of 754) with videos related to

Pageof 76
Sort By:
European Journal of Heart Failure|December 18, 2024
Mortality after high-risk myocardial infarction over the last 20 years: Insights from the VALIANT and PARADISE-MI trialsAlberto Foà, Maria A Pabon, Eugene Braunwald, et al.
Transplantation|February 25, 2016
B-Type Natriuretic Peptide and Cardiac Troponin I Are Associated With Adverse Outcomes in Stable Kidney Transplant RecipientsPetr Jarolim, Brian L Claggett, Michael J Conrad, et al.
Journal of the American Heart Association|September 23, 2020
NT-proBNP by Itself Predicts Death and Cardiovascular Events in High-Risk Patients With Type 2 Diabetes MellitusMarcus V B Malachias, Pardeep S Jhund, Brian L Claggett, et al.
JACC. Heart Failure|April 15, 2019
Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection FractionLi Shen, Pardeep S Jhund, Kieran F Docherty, et al.
Circulation|September 15, 2004
Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trialDavid Aguilar, Scott D Solomon, Lars Køber, et al.
Circulation|November 23, 2005
Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT)Harvey D White, Philip E G Aylward, Zhen Huang, et al.
European Journal of Heart Failure|February 14, 2015
Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) ProgrammeAthar A Badar, Ana C Perez-Moreno, Nathaniel M Hawkins, et al.
European Heart Journal|November 8, 2024
Centrally adjudicated vs. investigator-reported outcomes in randomized heart failure trialsSimon Wandel, Akshay S Desai, Chien-Wei Chen, et al.
European Journal of Heart Failure|December 26, 2006
Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARMEldrin F Lewis, Gervasio A Lamas, Eileen O'Meara, et al.
European Heart Journal|January 26, 2007
Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and functionMaria Amigoni, Alessandra Meris, Jens Jakob Thune, et al.
Pageof 76

Showing results (621-630 of 754) with videos related to

Sort By:
Pageof 76
European Journal of Heart Failure|December 18, 2024
Mortality after high-risk myocardial infarction over the last 20 years: Insights from the VALIANT and PARADISE-MI trialsAlberto Foà, Maria A Pabon, Eugene Braunwald, et al.
Transplantation|February 25, 2016
B-Type Natriuretic Peptide and Cardiac Troponin I Are Associated With Adverse Outcomes in Stable Kidney Transplant RecipientsPetr Jarolim, Brian L Claggett, Michael J Conrad, et al.
Journal of the American Heart Association|September 23, 2020
NT-proBNP by Itself Predicts Death and Cardiovascular Events in High-Risk Patients With Type 2 Diabetes MellitusMarcus V B Malachias, Pardeep S Jhund, Brian L Claggett, et al.
JACC. Heart Failure|April 15, 2019
Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection FractionLi Shen, Pardeep S Jhund, Kieran F Docherty, et al.
Circulation|September 15, 2004
Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trialDavid Aguilar, Scott D Solomon, Lars Køber, et al.
Circulation|November 23, 2005
Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT)Harvey D White, Philip E G Aylward, Zhen Huang, et al.
European Journal of Heart Failure|February 14, 2015
Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) ProgrammeAthar A Badar, Ana C Perez-Moreno, Nathaniel M Hawkins, et al.
European Heart Journal|November 8, 2024
Centrally adjudicated vs. investigator-reported outcomes in randomized heart failure trialsSimon Wandel, Akshay S Desai, Chien-Wei Chen, et al.
European Journal of Heart Failure|December 26, 2006
Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARMEldrin F Lewis, Gervasio A Lamas, Eileen O'Meara, et al.
European Heart Journal|January 26, 2007
Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and functionMaria Amigoni, Alessandra Meris, Jens Jakob Thune, et al.
Pageof 76